UBS has recently initiated Clover Health Investments Corp (CLOV) stock to Neutral rating, as announced on October 7, 2024, according to Finviz. Earlier, on February 2, 2022, Cowen had raised the stock from a Underperform to Market Perform, setting a price target of $3 for CLOV stock. Canaccord Genuity also initiated Buy rating with a price target of $6. Additionally, SVB Leerink initiated Mkt Perform rating on January 19, 2022, with a target price of $3. Citigroup analysts, in their report published on January 10, 2022, also resumed Neutral rating and set a price target of $9 for Clover Health Investments Corp’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Clover Health Investments Corp (CLOV) Stock Trading Recap
On Friday, Clover Health Investments Corp (CLOV) stock saw a modest uptick, ending the day at $4.07 which represents a slight increase of $0.12 or 3.04% from the prior close of $3.95. The stock opened at $4.11 and touched a low of $4 during the day, reaching a high of $4.22. The volume of shares traded was 7.73 million falling short of the average volume of 8.68 million.
CLOV Stock Performance and Moving Averages
In recent trading, Clover Health Investments Corp (CLOV) stock price has shown some volatility, fluctuating 0.74% over the last five trades and 46.93% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 507.37%, and it has gained 157.59% in the previous three months. Currently, CLOV is trading at 23.07%, 41.03%, and 175.73% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, CLOV, a Healthcare sector stock, is trading -5.02% below its 52-week high but remains 571.62% above its 52-week low. The Average True Range (ATR) (14 days) of 0.28 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Clover Health Investments Corp’s Profitability and Valuation Ratios
Clover Health Investments Corp’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -6.38% and a profit margin of -7.32%, with a gross margin of 507.37%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Clover Health Investments Corp’s market capitalization stands at $2.02 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 1.2, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 6.03, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 24.49% of Clover Health Investments Corp (CLOV)’s shares, while financial institutions hold 14.80%.